Hoe verhoudt BIOC's PS Ratio zich tot zijn concurrenten?

BIOC is duur op basis van de Price-To-Sales -ratio ( 2 x) vergeleken met het gemiddelde van de peer ( 1.7 x).

Hoe verhoudt BIOC's PS Ratio zich tot andere bedrijven in de US Biotechs industrie?

BIOC is een goede waarde op basis van de Price-To-Sales -ratio ( 2 x) vergeleken met het US Biotechs -industriegemiddelde ( 9.9 x).

Wat is BIOC's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

BIOC is duur op basis van de Price-To-Sales Ratio ( 2 x) vergeleken met de geschatte Fair Price-To-Sales Ratio ( 0 x).

Wat is de reële prijs van BIOC als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van BIOC te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Biocept (Nasdaq:BIOC) - Aandelenkoers, Nieuws & Analyse

BIOC Overzicht aandelen

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Meer informatie

BIOC fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 67.14% per jaar groeien

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( $3M )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft minder dan 1 jaar cash runway

+ 2 meer risico's

Biocept, Inc. Concurrenten

Fresh2 Group

NasdaqCM:FRES

US$2.5m

Aditxt

NasdaqCM:ADTX

US$3.5m

AquaBounty Technologies

NasdaqCM:AQB

US$3.9m

Molecular Templates

NasdaqCM:MTEM

US$2.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Biocept
Historische aandelenkoersen
Huidige aandelenkoers	US$1.02
52 Week Hoogtepunt	US$27.00
52 Week Laag	US$0.80
Bèta	0.59
11 maand verandering	-38.92%
3 maanden verandering	-13.56%
1 Jaar Verandering	-95.67%
33 jaar verandering	-99.28%
5 jaar verandering	-99.85%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Apr 17

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Aug 19

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Jul 03

Biocept and CLEARED4 ink collaboration agreement

Jun 09

Biocept enters COVID-19 testing partnership

Apr 28

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Mar 13

Rendement voor aandeelhouders

	BIOC	US Biotechs	US Markt
7D	-3.8%	4.0%	2.0%
1Y	-95.7%	18.0%	32.4%

Rendement versus industrie: BIOC presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 18 % opleverde.

Rendement versus markt: BIOC presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.4 % opleverde.

Prijsvolatiliteit

Is BIOC's price volatile compared to industry and market?
BIOC volatility
BIOC Average Weekly Movement	20.9%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van BIOC is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 21% ) van BIOC is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1997	50	Antonino Morales	biocept.com

Biocept, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Biocept zich tot de beurswaarde?
BIOC fundamentele statistieken
Marktkapitalisatie	US$2.68m
Inkomsten(TTM)	-US$30.61m
Inkomsten(TTM)	US$1.36m

2.0x

P/S-verhouding

-0.1x

Koers/Winstverhouding

Is BIOC overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BIOC resultatenrekening (TTM)
Inkomsten	US$1.36m
Kosten van inkomsten	US$15.66m
Brutowinst	-US$14.30m
Overige uitgaven	US$16.30m
Inkomsten	-US$30.61m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-11.66
Brutomarge	-1,054.09%
Nettowinstmarge	-2,255.49%
Schuld/Eigen Vermogen Verhouding	181.4%

Hoe presteerde BIOC op de lange termijn?

Bekijk historische prestaties en vergelijking

BIOC Overzicht aandelen

Beloningen

Risicoanalyse

Biocept, Inc. Concurrenten

NasdaqCM:FRES

US$2.5m

NasdaqCM:ADTX

US$3.5m

NasdaqCM:AQB

US$3.9m

NasdaqCM:MTEM

US$2.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index

Biocept's Securities To Be Delisted from Nasdaq

Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer

New minor risk - Revenue size

Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)

Recent updates

Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index

Biocept's Securities To Be Delisted from Nasdaq

Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer

New minor risk - Revenue size

Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)

Biocept, Inc. Announces Executive Changes

Biocept Expects to Receive Non-Compliance Notice Form Nasdaq

No longer forecast to breakeven

No longer forecast to breakeven

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Forecast to breakeven in 2025

Biocept, Inc. Appoints Quyen Dao-Haddock to the Board of Directors

Biocept, Inc. announced delayed 10-Q filing

Biocept Receives Non-Compliance Letter from Nasdaq

Biocept, Inc. Expands Commercial Offering of Cnside(Tm) Assay to Most Cancers That Metastasize to the Central Nervous System

Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc., Annual General Meeting, Jun 10, 2022

Biocept, Inc. announced delayed annual 10-K filing

Biocept, Inc. Appoints Philippe Marchand as Chief Operating Officer

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocept, Inc. Announces Management Changes

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

Investor sentiment improved over the past week

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)

Biocept, Inc. Implements Covid-19 Testing Program at Select California Community Colleges

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Biocept and CLEARED4 ink collaboration agreement

Consensus revenue estimates increase to US$37.5m

First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)

Price target decreased to US$12.00

Biocept enters COVID-19 testing partnership

Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load

Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients

New 90-day high: US$6.70

We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

New 90-day high: US$6.23

Biocept, Inc. Enters into Laboratory Services Agreements with Independent Physician Associations

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Biocept, Inc. Announces to Receives More Than 150,000 Samples for Covid-19 RT-PCR Testing

Biocept, Inc.'s Target Selector™ Liquid Biopsy Demonstrate High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations, earnings disappoint

Biocept's assays viable and sensitive for detecting tumor cells and biomarkers

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations, earnings disappoint